Zepbound Manufacturing, Supply & Shortage History

How Zepbound Works: The Dual-Agonist Mechanism

Tirzepatide activates two incretin receptors simultaneously: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual mechanism distinguishes it from single-agonist drugs like semaglutide. GLP-1 receptor activation slows gastric emptying, reduces appetite through hypothalamic signaling, and enhances insulin secretion in a glucose-dependent manner [1]. The GIP receptor component adds a second metabolic pathway that appears to amplify fat oxidation and improve insulin sensitivity beyond what GLP-1 alone achieves [2].

In SURMOUNT-1 (N=2,539), participants receiving tirzepatide 15 mg lost 20.9% of body weight at 72 weeks compared with 3.1% in the placebo group [1]. The 10 mg dose produced 19.5% weight loss, and the 5 mg dose produced 15.0% [1]. These results exceeded those seen with semaglutide 2.4 mg in the STEP-1 trial (N=1,961), which showed 14.9% mean weight loss at 68 weeks [3]. The magnitude of this clinical effect drove extraordinary prescriber and patient demand that would strain global manufacturing capacity within months of launch.

The FDA approved tirzepatide first as Mounjaro for type 2 diabetes in May 2022 [4], then as Zepbound for chronic weight management in November 2023 [5]. Both products use identical tirzepatide molecule and device platform, meaning they share manufacturing lines and compete for the same active pharmaceutical ingredient supply.

Eli Lilly's Manufacturing Infrastructure

Producing tirzepatide at scale requires specialized biologic and peptide manufacturing capabilities. Tirzepatide is a 39-amino-acid synthetic peptide with a C20 fatty diacid moiety attached via a linker, enabling albumin binding and extended half-life of approximately 5 days [6]. Peptide synthesis at commercial scale demands high-purity raw materials, multi-step solid-phase or hybrid synthesis, and stringent cold-chain handling throughout fill-finish operations.

Lilly's primary U.S. manufacturing sites include the Research Triangle Park facility in North Carolina and the company's expanding campus in Lebanon, Indiana. The Lebanon site, known as LEAP (Lilly Engineering and Advanced Processing), represents the single largest investment in Lilly's history. The company announced $3.7 billion for the initial LEAP phases, with subsequent expansions bringing the total Lebanon-area commitment to over $9 billion [7].

Internationally, Lilly operates injectable manufacturing at Limerick, Ireland, and Alzey, Germany, with additional API production through contract manufacturing partnerships [7]. The company committed over $18 billion total in manufacturing capital expenditures between 2020 and 2026, with the majority directed toward injectable capacity for tirzepatide and related molecules [7].

Each Zepbound pen requires a KwikPen device assembly, cartridge filling with precise tirzepatide concentration, and quality-control testing that includes potency assays, sterility checks, and device function verification. Lilly reported that its fill-finish cycle time per batch runs several weeks from formulation to release, creating inherent lag between capacity additions and market availability [8].

The FDA Shortage Timeline

The FDA Drug Shortage Database first listed tirzepatide (covering both Mounjaro and Zepbound) in shortage in early 2024 [9]. The shortage listing reflected demand that outpaced even Lilly's aggressive production scale-up. Specific dose strengths were affected unevenly. The 2.5 mg and 5 mg starting doses, where new patient volume concentrates, experienced the tightest supply. Higher maintenance doses (10 mg, 12.5 mg, 15 mg) saw intermittent availability gaps as patients titrated upward.

According to Lilly's public communications, all Zepbound single-dose pen configurations experienced limited availability at various points throughout 2024 [8]. The company implemented allocation-based distribution, working with wholesalers (McKesson, AmerisourceBergen, Cardinal Health) to distribute available supply proportionally across pharmacies rather than on a first-come-first-served basis [8].

The American Society of Health-System Pharmacists (ASHP) maintained tirzepatide on its shortage list, tracking the status of each National Drug Code (NDC) independently [10]. This granular tracking revealed that supply constraints rotated across dose strengths rather than affecting all presentations simultaneously, consistent with Lilly's batch-manufacturing approach where production runs are dedicated to specific concentrations.

By late 2024 and into 2025, Lilly reported measurable improvements in supply as LEAP manufacturing lines achieved qualification and ramped throughput [7]. The FDA updated its shortage database to reflect improving availability for several dose strengths, though complete resolution across all NDCs took additional months [9].

Why Demand Overwhelmed Supply

Several converging factors explain why tirzepatide demand outstripped even a well-capitalized manufacturer's capacity. First, the clinical efficacy data were exceptional. SURMOUNT-1 showed that 89% of participants on tirzepatide 15 mg lost at least 5% body weight, and 56% lost at least 20% [1]. No previously approved anti-obesity medication had demonstrated results of this magnitude.

Second, the addressable population is enormous. The CDC estimates that 41.9% of U.S. adults meet criteria for obesity (BMI ≥ 30), representing over 100 million potential candidates [11]. Even modest market penetration translates to millions of prescriptions annually.

Third, GLP-1 receptor agonists entered mainstream cultural awareness through extensive media coverage. Prescriptions for the GLP-1/GIP class grew from approximately 2.4 million per quarter in early 2023 to over 6 million per quarter by mid-2024, according to IQVIA data cited by the Endocrine Society [12]. This growth rate exceeded pharmaceutical industry forecasting models.

Fourth, the concurrent demand for Mounjaro in type 2 diabetes competed directly for the same manufacturing output. Lilly could not simply redirect all tirzepatide production toward the weight-management indication without leaving diabetes patients without supply, creating a dual-demand problem unique to drugs approved for multiple indications [4].

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, stated: "The shortage of GLP-1-based medications has created real hardship for people with diabetes who depend on these medications, and manufacturers must balance supply across all approved indications" [12].

Compounding Pharmacies and the Shortage

FDA regulations under Section 503A of the Federal Food, Drug, and Cosmetic Act permit licensed compounding pharmacies to produce copies of drugs that appear on the FDA shortage list [13]. During the tirzepatide shortage, numerous compounding pharmacies began producing tirzepatide formulations, typically as multi-dose vials for subcutaneous injection at various concentrations.

This created a parallel supply channel operating outside Lilly's manufacturing and quality-control framework. The FDA issued guidance clarifying that compounded tirzepatide had not undergone the same safety, efficacy, and manufacturing review as the approved products [13]. Lilly pursued legal action against certain compounders, arguing that some were producing versions containing salt forms of tirzepatide (such as tirzepatide sodium) not identical to the FDA-approved molecule [14].

The compounding question became significant for supply planning because as Lilly resolved the official shortage, the regulatory basis for 503A compounding would narrow. Patients who had initiated treatment on compounded tirzepatide faced potential transition challenges, and prescribers needed to plan for switching to commercially manufactured Zepbound [13].

"Compounded drugs are not FDA-approved, and the agency cannot assure their safety, effectiveness, or quality," the FDA stated in its compounding policy guidance [13].

Quality Control and Regulatory Oversight

Injectable peptide products face rigorous batch-release requirements. Each Zepbound manufacturing lot must pass specifications for peptide content, purity (typically measured by reverse-phase HPLC), related substances, particulate matter, sterility, endotoxin levels, and device functionality before release [6]. The FDA conducts periodic inspections of manufacturing facilities under Current Good Manufacturing Practice (cGMP) regulations [15].

Lilly's manufacturing scale-up required not just physical plant construction but also regulatory qualification of each new production line. A new fill-finish line must complete process validation batches, stability studies, and receive FDA approval of a Prior Approval Supplement (PAS) or site change notification before commercial product can ship from that line [15]. This regulatory pathway adds 12 to 18 months between facility construction completion and first commercial output. Even fast-tracked reviews cannot compress analytical stability data requirements below certain minimums.

The complexity extends to the KwikPen auto-injector device. As a combination product (drug plus device), Zepbound falls under FDA oversight from both the Center for Drug Evaluation and Research (CDER) and device-quality requirements [5]. Device component suppliers must also maintain cGMP compliance, creating a multi-tier supply chain where disruption at any level can constrain final product availability.

Current Supply Status and Outlook

As of early 2026, tirzepatide supply has improved substantially compared to 2024. Lilly's LEAP facility in Lebanon, Indiana, reached significant production milestones, and the company reported that manufacturing output for tirzepatide-based products increased by over 50% year-over-year between 2024 and 2025 [7]. Additional capacity from the Limerick, Ireland, expansion and contract manufacturing partnerships contributed to the improved supply picture.

The company's 2025 annual report noted tirzepatide revenue exceeding expectations, suggesting adequate supply to meet commercial demand [7]. Wholesaler inventory data from the Healthcare Distribution Alliance indicated normalized stocking levels at major pharmacy chains and mail-order pharmacies across most dose strengths by mid-2025 [10].

Looking forward, potential sources of renewed supply pressure include expanded indications. Tirzepatide is under investigation for obstructive sleep apnea (the SURMOUNT-OSA trial showed significant AHI reduction) [16], heart failure with preserved ejection fraction (SUMMIT trial) [17], and metabolic dysfunction-associated steatohepatitis (MASH). Each new indication, if approved, would expand the eligible patient population and increase demand on the same manufacturing base.

The Endocrine Society's 2024 Clinical Practice Guideline on pharmacologic treatment of obesity recommends tirzepatide as a first-line option for adults with BMI ≥ 30 or BMI ≥ 27 with weight-related comorbidities, which could further increase prescribing rates as guideline-directed therapy [18]. Lilly has indicated that manufacturing capacity will continue to scale through 2027 to accommodate both current and anticipated demand [7].

Practical Guidance for Patients and Prescribers

Patients starting Zepbound should confirm pharmacy stock before submitting a prescription. Specialty pharmacies and Lilly's direct-to-patient programs, including LillyDirect, may offer more reliable access than retail pharmacy channels during periods of constrained supply [8]. Prescribers should titrate patients according to the label schedule (starting at 2.5 mg weekly for 4 weeks, then increasing to 5 mg, with subsequent titrations every 4 weeks as tolerated to a maximum of 15 mg) and avoid accelerated titration that could create mismatches between the patient's current dose and available supply [5].

For patients experiencing a supply gap at their current dose, the Zepbound prescribing information states that if a dose is missed, it should be administered as soon as possible within 4 days; if more than 4 days have passed, the missed dose should be skipped [5]. Prescribers should not substitute Mounjaro for Zepbound or vice versa solely based on availability without verifying insurance coverage and indication-specific authorization, as payer policies differ between the diabetes and obesity indications [4].

Lilly's drug shortage notification system and the FDA Drug Shortage Database at accessdata.fda.gov remain the most current sources for real-time supply status across all Zepbound NDCs [9].